ReShape Lifesciences (OTCMKTS:RSLSD) & Check-Cap (NASDAQ:MBAI) Head to Head Survey

ReShape Lifesciences (OTCMKTS:RSLSD) and Check-Cap (NASDAQ:MBAI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Earnings & Valuation

This table compares ReShape Lifesciences and Check-Cap”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$610,000.00	0.00	-$81.15 million	N/A	N/A
Check-Cap	N/A	N/A	-$25.15 million	($2.77)	-0.66

Check-Cap has lower revenue, but higher earnings than ReShape Lifesciences.

Profitability

This table compares ReShape Lifesciences and Check-Cap’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-668.58%	-163.22%	-52.10%
Check-Cap	N/A	N/A	N/A

Insider & Institutional Ownership

1.1% of Check-Cap shares are held by institutional investors. 0.5% of Check-Cap shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Check-Cap has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for ReShape Lifesciences and Check-Cap, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0	0	0	0	0.00
Check-Cap	1	0	0	0	1.00

Given ReShape Lifesciences’ higher possible upside, analysts plainly believe ReShape Lifesciences is more favorable than Check-Cap.

Summary

Check-Cap beats ReShape Lifesciences on 7 of the 10 factors compared between the two stocks.

About ReShape Lifesciences

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.